Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Heilongjiang Eppen Biotech Co. Ltd. holds a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution activity is limited to 1 pending office action. This indicates a focused effort on a specific application or set of claims, rather than a broad or high-volume filing strategy at this time. This singular focus allows for a concentrated legal effort on one particular biological or pharmaceutical innovation.
The portfolio is being processed by 1 distinct examiner and is situated within 1 distinct art unit. This level of concentration suggests that the intellectual property being sought is specialized and falls under the purview of a single technical group. The involvement of only one art unit simplifies the prosecution process by centralizing the review within one department, which can lead to a more consistent application of technical standards.
STEADMAN, DAVID J is the busiest examiner for this portfolio, with 1 busiest examiner pending action. This examiner is the only official currently reviewing the company active applications. The fact that the busiest examiner pending count of 1 matches the total pending office actions indicates that the entire active workload is managed by this one individual, making their specific examination style a primary factor in the outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17753368 | ESCHERICHIA COLI-BASED RECOMBINANT STRAIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17753368 | ESCHERICHIA COLI-BASED RECOMBINANT STRAIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF | STEADMAN, DAVID J | 1656 | §103 | Final Rejection | — | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHeilongjiang Eppen Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David J Steadman has the most, with 1 of Heilongjiang Eppen Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
